🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525700-10-00
Completed Phase I

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers

2026-525700-10-00 · tracked via the Priya Life Science EU tracker
Sponsor
Syremis Therapeutics Ltd.
Sponsor type
Pharmaceutical company
Therapeutic area
Mental Disorders
Decision date
08/06/2026
Enrollment target
280
Sites
France

Condition studied

Schizophrenia

Eligibility

Age group
18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525700-10-00 on CTIS ↗ ← All trials in the EU